Your browser doesn't support javascript.
loading
Design, synthesis, and biological evaluation of Bcr-Abl PROTACs to overcome T315I mutation
Acta Pharmaceutica Sinica B ; (6): 1315-1328, 2021.
Article in English | WPRIM | ID: wpr-881201
ABSTRACT
Bcr-Abl threonine 315 to isoleucine 315 (T315I) gatekeeper mutation induced drug resistance remains an unmet clinical challenge for the treatment of chronic myeloid leukemia (CML). Chemical degradation of Bcr-Abl

Full text: Available Index: WPRIM (Western Pacific) Language: English Journal: Acta Pharmaceutica Sinica B Year: 2021 Type: Article

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: WPRIM (Western Pacific) Language: English Journal: Acta Pharmaceutica Sinica B Year: 2021 Type: Article